Brown Shipley & Co’s Harvard Bioscience HBIO Stock Holding History

Brown Shipley & Co’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.94K	Hold	478	–	–	﹤0.01%	75
2026 Q1	$2.33K	Hold	478	–	–	﹤0.01%	78
2025 Q4	$3.2K	Hold	478	–	–	﹤0.01%	68
2025 Q3	$2.1K	Hold	478	–	–	﹤0.01%	63
2025 Q2	$2.12K	Hold	478	–	–	﹤0.01%	66
2025 Q1	$2.71K	Hold	478	–	–	﹤0.01%	63
2024 Q4	$10.1K	Hold	478	–	–	0.01%	62
2024 Q3	$12.9K	Hold	478	–	–	0.01%	64
2024 Q2	$13.6K	Buy	478 +4	+0.8%	+$140	0.01%	67
2024 Q1	$20.2K	Sell	474 -4	-0.8%	-$180	0.01%	91
2023 Q4	$25.6K	Hold	478	–	–	0.01%	78
2023 Q3	$20.6K	Hold	478	–	–	0.01%	83
2023 Q2	$26.3K	Hold	478	–	–	0.01%	96
2023 Q1	$20.1K	Buy	+478	New	+$14.2K	0.01%	102

Other funds holding HBIO

Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Brown Shipley & Co's HBIO Position: Q2 2026 in Review

Brown Shipley & Co held its Harvard Bioscience (HBIO) position steady in Q2 2026 at 478 shares worth $2.94K. The position accounts for ﹤0.01% of the portfolio, ranked #75.

Brown Shipley & Co first reported a position in HBIO in Q1 2023 and has held it in 14 quarters since. The position peaked at $26.3K in Q2 2023. 3 funds tracked by Wall St. Rank hold HBIO as of Q2 2026.

Brown Shipley & Co held 478 shares of Harvard Bioscience worth $2.94K as of Q2 2026.
Brown Shipley & Co left its Harvard Bioscience share count unchanged in Q2 2026.
Harvard Bioscience made up ﹤0.01% of Brown Shipley & Co's portfolio in Q2 2026, its #75 holding.
Brown Shipley & Co first reported a position in Harvard Bioscience in Q1 2023 and has held it in 14 quarters since.
Brown Shipley & Co's Harvard Bioscience position peaked at $26.3K in Q2 2023.
3 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2026.

Based on Brown Shipley & Co's 13F filing for Q2 2026, filed 14 Jul 2026.